tiprankstipranks
PepGen treatment of Duchenne Muscular Dystrophy gets FDA orphan designation
PremiumThe FlyPepGen treatment of Duchenne Muscular Dystrophy gets FDA orphan designation
2M ago
PepGen price target lowered to $20 from $21 at Wedbush
PremiumThe Fly
PepGen price target lowered to $20 from $21 at Wedbush
2M ago
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
PremiumPress Releases
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
2M ago
PepGen Inc. Secures Funding to Advance Research Programs
PremiumCompany AnnouncementsPepGen Inc. Secures Funding to Advance Research Programs
3M ago
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
PremiumPress Releases
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
3M ago
PepGen prices 7.53M shares at $10.635 in underwritten public offering
PremiumThe Fly
PepGen prices 7.53M shares at $10.635 in underwritten public offering
3M ago
PepGen announces first patient dosed in CONNECT1-EDO51 Phase 2 trial
PremiumThe FlyPepGen announces first patient dosed in CONNECT1-EDO51 Phase 2 trial
4M ago
PepGen doses first patient in Phase 1 FREEDOM-DM1 trial
PremiumThe Fly
PepGen doses first patient in Phase 1 FREEDOM-DM1 trial
4M ago
PepGen announces appointment of Mayer to board of directors
PremiumThe Fly
PepGen announces appointment of Mayer to board of directors
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100